Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 172 results found. Search for [ Drug firm Lupin ]

Results 1 to 21 of 172
BusinessToday.In
March 5, 2020
Stocks to watch today on March 6: YES Bank, Tata Power, Cadila, Lupin, PNB, Union Bank among others are the top stocks to watch out for in Friday's trading session


BusinessToday.In
January 20, 2020
Share Market Update: BSE Sensex ended 400 points lower at 41,528 and NSE Nifty traded 121 points lower at 12,230 by the closing bell.


PTI
January 18, 2020
The USFDA inspection for the API facility at Vizag was carried out between January 13, 2020 and January 17, 2020, and it closed five 483 observations


PTI
January 11, 2020
A Prior Approval Inspection was carried out by the United States Food and Drug Administration at Lupin's Nagpur oral solid dosage manufacturing facility between January 6-10, 2020


PB Jayakumar
December 30, 2019
The USFDA's Office of Manufacturing Quality (OMQ) at the Centre for Drug Evaluation Research (CDER) evaluates compliance with cGMP for drugs based on inspection reports and evidence gathered by USFDA investigators


BusinessToday.In
December 17, 2019
Share Market Update: Sensex rose to its lifetime high of 41,401 in Tuesday's trade, NSE Nifty cliamed a all-time high of 12,182 today


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


PB Jayakumar
New Delhi, November 12, 2019
The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019


PB Jayakumar
New Delhi, November 7, 2019
Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year


BusinessToday.In
New Delhi, November 6, 2019
Lupin Q2 results: Consolidated revenue from operations of the pharma major increased 10.3 per cent year-on-year (YoY) to Rs 4,359.7 crore in Q2FY20 as against Rs 3,951 crore in Q2FY19


Manu Kaushik
New Delhi, October 30, 2019
Even though Gangwal stands on thin ice if the powers entrusted in the shareholders' agreement are considered; Bhatia has much more to lose if this matter escalates further


BusinessToday.In
New Delhi, October 7, 2019
Weighed down by USFDA observations, share price of Aurobindo Pharma declined as much as 20.65 per cent to hit a 52-week low of Rs 450 on the BSE, after opening tad lower at Rs 560 against previous close level of Rs 567.15 on the BSE


PB Jayakumar
New Delhi, September 24, 2019
Ranitidine, an old molecule with sales of $412.4 million is found to have cancer-causing impurities


PTI
August 7, 2019
Drug firm Lupin on Wednesday reported a 49.46 per cent rise in consolidated net profit to Rs 303.05 crore for the quarter ended June 30, 2019 on account of robust sales in India and overseas.


PB Jayakumar
New Delhi, July 22, 2019
Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years


Joe C Mathew
New Delhi, July 22, 2019
Indian companies are finally getting down to cracking the Japanese market


PTI
June 4, 2019



PTI
May 15, 2019



PTI
May 15, 2019



BusinessToday.In
May 15, 2019
Share Market Updates: Shedding gains of the trading session Wednesday, benchmark indices closed in the red. Other major indices gave up all intraday gains to turn negative in trade as well.


PAGES 1 OF 9  12345